Smith & Nephew (LON:SN) PT Raised to GBX 1,381

Smith & Nephew (LON:SN) had its target price upped by investment analysts at JPMorgan Chase & Co. from GBX 1,300 ($16.33) to GBX 1,381 ($17.35) in a research report issued on Thursday, Digital Look reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 41.41% from the company’s previous close.

Several other research firms have also commented on SN. Berenberg Bank reissued a “buy” rating and issued a GBX 1,450 ($18.21) target price on shares of Smith & Nephew in a report on Thursday. Royal Bank of Canada reissued an “outperform” rating and issued a GBX 1,500 ($18.84) price objective on shares of Smith & Nephew in a research note on Friday, April 5th. Finally, Barclays restated an “equal weight” rating and set a GBX 1,150 ($14.45) price objective on shares of Smith & Nephew in a research report on Friday, February 9th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, Smith & Nephew has a consensus rating of “Moderate Buy” and an average price target of GBX 1,370.25 ($17.21).

Smith & Nephew Stock Performance

LON SN traded down GBX 2.40 ($0.03) during trading on Thursday, reaching GBX 976.60 ($12.27). The company’s stock had a trading volume of 3,690,163 shares, compared to its average volume of 343,671. The company has a current ratio of 1.77, a quick ratio of 0.84 and a debt-to-equity ratio of 59.11. Smith & Nephew has a 12 month low of GBX 887 ($11.14) and a 12 month high of GBX 1,316.75 ($16.54). The firm has a 50 day moving average price of GBX 1,024.48 and a 200 day moving average price of GBX 1,034.66. The firm has a market capitalization of £8.54 billion, a price-to-earnings ratio of 4,069.17, a price-to-earnings-growth ratio of 0.46 and a beta of 0.51.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.